These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 3100357

  • 41. The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis.
    Surrey ES, Gambone JC, Lu JK, Judd HL.
    Fertil Steril; 1990 Apr; 53(4):620-6. PubMed ID: 2108056
    [Abstract] [Full Text] [Related]

  • 42. Hormonal changes associated with Danazol therapy.
    Wood GP, Wu CH, Flickinger GL, Mikhail G.
    Obstet Gynecol; 1975 Mar; 45(3):302-4. PubMed ID: 1113947
    [Abstract] [Full Text] [Related]

  • 43. Medical treatment of endometriosis: a comparison of the suppressive effects of danazol and nafarelin on reproductive hormones.
    Hickok LR, Burry KA, Cohen NL, Moore DE, Dahl KD, Soules MR.
    Fertil Steril; 1991 Oct; 56(4):622-7. PubMed ID: 1833245
    [Abstract] [Full Text] [Related]

  • 44. [The new synthetic gestagen danazol in the treatment of endometriosis, fibrosystic disease of the breast and prolonged primary infertility (author's transl)].
    Goebel R, Rjosk HK.
    Geburtshilfe Frauenheilkd; 1978 Nov; 38(11):932-40. PubMed ID: 152220
    [No Abstract] [Full Text] [Related]

  • 45. Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study.
    Fedele L, Marchini M, Bianchi S, Baglioni A, Zanotti F.
    Fertil Steril; 1993 Jun; 59(6):1191-5. PubMed ID: 8495764
    [Abstract] [Full Text] [Related]

  • 46. TRH test before, during, and after long-term danazol treatment in patients with endometriosis.
    Panidis DK, Matalliotakis IM, Vayonas MD, Vlassis GD, Kalogeropoulos AP.
    Hum Reprod; 1989 Nov; 4(8):903-5. PubMed ID: 2515206
    [Abstract] [Full Text] [Related]

  • 47. The hypothalamic-pituitary-ovarian axis in patients with endometriosis is suppressed by leuprolide acetate but not by danazol.
    Sakata M, Ohtsuka S, Kurachi H, Miyake A, Terakawa N, Tanizawa O.
    Fertil Steril; 1994 Mar; 61(3):432-7. PubMed ID: 8137962
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Uterine leiomyoma: treatment with LHRH agonist.
    Maheux R, Lemay A.
    Prog Clin Biol Res; 1986 Mar; 225():297-311. PubMed ID: 3097669
    [No Abstract] [Full Text] [Related]

  • 50. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Lemay A, Quesnel G.
    Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
    [Abstract] [Full Text] [Related]

  • 51. Endocrine effects of danazol in the treatment of endometriosis.
    Bevan JR, Dowsett M, Jeffcoate SL.
    Br J Obstet Gynaecol; 1984 Feb; 91(2):160-6. PubMed ID: 6538094
    [Abstract] [Full Text] [Related]

  • 52. [Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)].
    Masaoka K, Kitazawa M, Kumasaka T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):405-11. PubMed ID: 2501437
    [Abstract] [Full Text] [Related]

  • 53. [Hormonal changes in buserelin therapy].
    Fuchs U, Zwirner M.
    Zentralbl Gynakol; 1989 Apr; 111(18):1236-40. PubMed ID: 2511705
    [Abstract] [Full Text] [Related]

  • 54. A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis.
    Tummon IS, Pepping ME, Binor Z, Radwanska E, Dmowski WP.
    Fertil Steril; 1989 Mar; 51(3):390-4. PubMed ID: 2522062
    [Abstract] [Full Text] [Related]

  • 55. Combined use of a long-acting gonadotropin-releasing hormone agonist and low-dose danazol in advanced stage endometriosis.
    Ugur M, Senöz S, Gökmen O.
    Eur J Obstet Gynecol Reprod Biol; 1996 Sep; 68(1-2):155-8. PubMed ID: 8886699
    [Abstract] [Full Text] [Related]

  • 56. Zoladex versus danazol in the treatment of pelvic endometriosis: effects on plasma lipid risk factors.
    Crook D, Gardner R, Worthington M, Nolan J, Stevenson JC, Shaw RW.
    Horm Res; 1989 Sep; 32 Suppl 1():157-60. PubMed ID: 2533147
    [Abstract] [Full Text] [Related]

  • 57. Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol.
    Lemay A, Brideau NA, Forest JC, Dodin S, Maheux R.
    Clin Endocrinol (Oxf); 1991 Oct; 35(4):305-10. PubMed ID: 1836425
    [Abstract] [Full Text] [Related]

  • 58. A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis.
    Cirkel U, Ochs H, Schneider HP.
    Eur J Obstet Gynecol Reprod Biol; 1995 Mar; 59(1):61-9. PubMed ID: 7781864
    [Abstract] [Full Text] [Related]

  • 59. [Treatment of endometriosis with the GnRH agonist buserelin (Suprecur): a multicenter study].
    Schindler AE, Bühler K, Mettler L, Fuchs U, Cirkel U, Ochs H, Schweppe KW, Koch R.
    Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):569-73. PubMed ID: 8001754
    [Abstract] [Full Text] [Related]

  • 60. Danazol and prolactin status in patients with endometriosis.
    Wallace AM, Lees DA, Roberts AD, Gray CE, McLaren EH, Low RA.
    Acta Endocrinol (Copenh); 1984 Dec; 107(4):445-9. PubMed ID: 6440389
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.